Loading institutional data...
Loading institutional data...
Held by 1,017 of 5,944 reporting institutions (99th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $156.34 today, the market must believe free cash flow compounds 15.1%/yr for a decade (off $1.3B normalized FCF).
The market's 15.1% is more optimistic than its 9-yr track record.
2-stage DCF · 0.28B shares · net debt $1.6B
mean 9.6% · volatility σ 29% · implied rate exceeded in 3/9 yrs
Central path = implied 15.1%/yr growth; shaded band = ±1σ (29%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| A | $44.3B | 34.2× | 25.9× | 6.4× | 6.7% | 52.4% | 18.8% | 19.3% | 12.9% | 1.9× | 1,017 |
Peers = companies sharing A's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 24% of free cash flow, leaving room to grow it and fund buybacks. Last year: $282M dividends + $425M buybacks = $707M returned on $1.2B FCF.
9 consecutive years of dividend increases · 17%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Modest payoff on reinvested capital. Current ROIC on all capital: 13%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~3.3% on $3.4B of debt.
Cash of $1.8B fully covers short-term debt of $304M.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
No standout strengths flagged.
Nothing notable to watch.
No material risks flagged.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 45.5 | 45.7 | 46.9 | 46.1 | 45.6 | 49.3 | 45.7 | 47.6 |
| R&D | 7.9 | 7.8 | 9.3 | 7.0 | 6.8 | 7.0 | 7.4 | 6.5 |
| SG&A | 28.3 | 28.3 | 28.0 | 25.6 | 23.9 | 23.9 | 24.1 | 24.6 |
| Operating Income | 18.4 | 18.2 | 15.8 | 21.3 | 23.6 | 19.8 | 22.9 | 21.3 |
| Income Tax | 12.8 | -2.9 | 2.3 | 2.4 | 3.7 | 1.4 | 3.6 | 1.9 |
| Net Income | 6.4 | 20.7 | 13.5 | 19.1 | 18.3 | 18.1 | 19.8 | 18.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on A: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.95B 100.0% | $6.51B 100.0% | $6.83B 100.0% | $6.85B 100.0% | $6.32B 100.0% | $5.34B 100.0% | $5.16B 100.0% | $4.91B 100.0% | $4.47B 100.0% | $4.20B 100.0% |
| Cost of Revenue | $3.31B 47.6% | $2.98B 45.7% | $3.37B 49.3% | $3.13B 45.6% | $2.91B 46.1% | $2.50B 46.9% | $2.36B 45.7% | $2.23B 45.5% | $2.06B 46.1% | $2.00B 47.7% |
| Cost of Products | — | — | — | — | — | — | — | — | $1.47B 32.8% | $1.46B 34.8% |
| Research & Development | $455.0M 6.5% | $479.0M 7.4% | $481.0M 7.0% | $467.0M 6.8% | $441.0M 7.0% | $495.0M 9.3% | $404.0M 7.8% | $387.0M 7.9% | $341.0M 7.6% | $329.0M 7.8% |
| Selling, General & Admin | $1.71B 24.6% | $1.57B 24.1% | $1.63B 23.9% | $1.64B 23.9% | $1.62B 25.6% | $1.50B 28.0% | $1.46B 28.3% | $1.39B 28.3% | $1.25B 28.0% | $1.25B 29.8% |
| Total Operating Expenses | $5.47B 78.7% | $5.02B 77.1% | $5.48B 80.2% | $5.23B 76.4% | $4.97B 78.7% | $4.49B 84.2% | $4.22B 81.8% | $4.01B 81.6% | $3.67B 82.0% | $3.59B 85.4% |
| Operating Income | $1.48B 21.3% | $1.49B 22.9% | $1.35B 19.8% | $1.62B 23.6% | $1.35B 21.3% | $846.0M 15.8% | $941.0M 18.2% | $904.0M 18.4% | $807.0M 18.0% | $615.0M 14.6% |
| Interest Expense | $112.0M 1.6% | $96.0M 1.5% | $95.0M 1.4% | $84.0M 1.2% | $81.0M 1.3% | $78.0M 1.5% | $74.0M 1.4% | $75.0M 1.5% | $79.0M 1.8% | $72.0M 1.7% |
| Interest & Investment Income | $62.0M 0.9% | $80.0M 1.2% | $51.0M 0.7% | $9.0M 0.1% | $2.0M 0.0% | $8.0M 0.1% | $36.0M 0.7% | $38.0M 0.8% | $22.0M 0.5% | $11.0M 0.3% |
| Other Income (Expense), net | $6.0M 0.1% | $49.0M 0.8% | $33.0M 0.5% | -$39.0M -0.6% | $92.0M 1.5% | $66.0M 1.2% | $16.0M 0.3% | $79.0M 1.6% | $53.0M 1.2% | -$10.0M -0.2% |
| Pretax Income | $1.44B 20.7% | $1.52B 23.4% | $1.34B 19.6% | $1.50B 22.0% | $1.36B 21.5% | $842.0M 15.8% | $919.0M 17.8% | $946.0M 19.3% | $974.0M 21.8% | $859.0M 20.4% |
| Income Tax Expense | $132.0M 1.9% | $232.0M 3.6% | $99.0M 1.4% | $250.0M 3.7% | $150.0M 2.4% | $123.0M 2.3% | -$152.0M -2.9% | $630.0M 12.8% | $119.0M 2.7% | $82.0M 2.0% |
| Net Income | $1.30B 18.8% | $1.29B 19.8% | $1.24B 18.1% | $1.25B 18.3% | $1.21B 19.1% | $719.0M 13.5% | $1.07B 20.7% | $316.0M 6.4% | $684.0M 15.3% | $462.0M 11.0% |
| Per Share | ||||||||||
| EPS (Basic) | $4.59 | $4.44 | $4.22 | $4.19 | $3.98 | $2.33 | $3.41 | $0.98 | $2.12 | $1.42 |
| EPS (Diluted) | $4.57 | $4.43 | $4.19 | $4.18 | $3.94 | $2.30 | $3.37 | $0.97 | $2.10 | $1.40 |
| Weighted Avg Shares (Basic) | 284.0M | 290.0M | 294.0M | 299.0M | 304.0M | 309.0M | 314.0M | 321.0M | 322.0M | 326.0M |
| Weighted Avg Shares (Diluted) | 285.0M | 291.0M | 296.0M | 300.0M | 307.0M | 312.0M | 318.0M | 325.0M | 326.0M | 329.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.